Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report) gapped down prior to trading on Thursday . The stock had previously closed at $39.99, but opened at $38.00. Ascentage Pharma Group International shares last traded at $39.46, with a volume of 4,862 shares.
Wall Street Analysts Forecast Growth
Separately, JPMorgan Chase & Co. assumed coverage on shares of Ascentage Pharma Group International in a research note on Thursday, March 27th. They issued an "overweight" rating for the company.
Check Out Our Latest Stock Report on AAPG
Ascentage Pharma Group International Price Performance
The company's 50-day moving average is $27.01. The company has a debt-to-equity ratio of 3.24, a current ratio of 1.26 and a quick ratio of 1.26.
Hedge Funds Weigh In On Ascentage Pharma Group International
A hedge fund recently bought a new stake in Ascentage Pharma Group International stock. Monashee Investment Management LLC bought a new position in shares of Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 159,942 shares of the company's stock, valued at approximately $3,511,000. Monashee Investment Management LLC owned 0.18% of Ascentage Pharma Group International as of its most recent filing with the Securities and Exchange Commission (SEC).
Ascentage Pharma Group International Company Profile
(
Get Free Report)
Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ascentage Pharma Group International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascentage Pharma Group International wasn't on the list.
While Ascentage Pharma Group International currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
